Overview

Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises

Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine if the use of ketamine, sniffed in the nose, is a safe and effective way to help reduce pain in pediatric sickle cell patients with pain crises in resource-limited settings.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Cameroon Baptist Convention Health
Collaborators:
Carolinas Medical Center
Muhimbili National Hospital
Treatments:
Ketamine
Criteria
Inclusion Criteria:

- Sickle cell disease (SCD)

- Vasoocclusive pain crisis

- Requiring analgesia

Exclusion Criteria:

- Anatomic variations of nose precluding intranasal medication administration

- Ketamine allergy

- Non-verbal

- Obtunded

- Pregnant

- Other acute SCD complications:

- Acute chest syndrome

- Sepsis

- Stroke

- Splenic sequestration

- Pulmonary embolism

- Acute osteomyelitis